Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Cancer care crowdfunding increasingly common, but rarely successful

2.

Radioligand Therapy Set to Transform Oncology Care

3.

Hemihedral resection not necessary for neuroendocrine surgery after appendicitis

4.

No increased risk of childhood cancer near UK nuclear sites, study finds

5.

Timely 'Nudges' Can Help Encourage More End-of-Life Conversations in Cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot